Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
Summary
Moderna and Merck announced that their experimental mRNA cancer vaccine helped stop melanoma, a type of skin cancer, from coming back or spreading in a late-stage trial. This success brings the vaccine closer to becoming a new treatment option for patients at high risk of cancer returning.Key Facts
- The vaccine is personalized and uses mRNA technology.
- It specifically targets melanoma, a serious skin cancer.
- The trial involved patients with a high risk of melanoma returning or spreading.
- Results showed the vaccine was effective in preventing cancer recurrence.
- This was a late-stage clinical trial, an important step before approval.
- The vaccine could extend the lives of melanoma patients.
- Moderna and Merck developed the vaccine together.
- Positive trial results move the vaccine closer to market availability.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
